Healthcare Whitepaper and Newsletter

Our multidimensional, purposeful, and credible market analysis will help accelerate your business growth and overcome challenges with a practical approach.
  • Home
  • Newsletter/Whitepaper
Cancer Care in the time of COVID
In Focus
Cancer Care in the time of COVID
The coronavirus outbreak has affected thousands of people in at least 186 countries which has also affected the cancer care delivery system apart from affecting the overall health system. Cancer patients are more susceptible to coronavirus infection than individuals without cancer as they are in an immunosuppressive state caused due to the malignancy and anticancer treatments like the chemotherapy and the radiation therapy.The purpose of this whitepaper is to represent an overview of the current cancer therapy scenario in the time of COVID-19. It is giving its readers a sneak peek into the world of the healthcare providers and human resource management systems, the risks, the challenges and the hurdles faced and how......
Read More
Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients Whitepaper
Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients
Over the years, the Oncology domain has experienced the entry of several treatment approaches. Therapeutic approaches such as surgery, radiation therapy, and chemotherapy form the conventional methods of combating cancers and are still the mainstays of cancer treatment; however, the recent emergence of immunotherapies, targeted therapies has also played an instrumental role in decreasing the cancer burden.
Go to Newsletter
Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic Purpura (ITP)
Immune thrombocytopenic purpura (ITP) is a disorder that results in the immune system killing its platelets. It results in excessive bleeding or bruising easily due to low levels of platelets. Worldwide, there are more than 200,000 people affected by ITP. The primary goal of the ITP treatment is to provide the patient with sufficient platelets rather than correcting the platelet count to normal levels.DelveInsight's brings another addition to its Newsletter portfolio, focusing on rare diseases of the blood.The newsletter offers an overview of the indication - Immune thrombocytopenic purpura (ITP), its epidemiological analysis, treatment goals, marketed therapies, unmet needs, ....
Go to Newsletter
Cancer Care in the time of COVID
Cancer Care in the time of COVID
The coronavirus outbreak has affected thousands of people in at least 186 countries which has also affected the cancer care delivery system apart from affecting the overall health system. Cancer patients are more susceptible to coronavirus infection than individuals without cancer as they are in an immunosuppressive state caused due to the malignancy and anticancer treatments like the chemotherapy and the radiation therapy.The purpose of this whitepaper is to represent an overview of the current cancer therapy scenario in the time of COVID-19. It is giving its readers a sneak peek into the world of the healthcare providers and human resource management systems, the risks, the challenges and the hurdles faced and how......
Go to Newsletter
Car-T Cell Therapy: A Journey From Challenges To Opportunities
Car-T Cell Therapy: A Journey From Challenges To Opportunities
With its innovative approach, chimeric antigen receptor T cell therapy created a new dawn in the age of cancer. Immunotherapy can be taken as a very powerful tool that can alter the immune system's picture. With the emergence of the CAR’s and the introductions of the designed killer T cells, CTL’s or cytotoxic T cells, one can attack the greatest villain, which is Cancer. CAR-T cell therapy is regarded as a revolutionary cancer therapy, which has a curative potential to show a paradigm shift in the cancer treatment. The purpose of this whitepaper is to represent the rapidly emerging ....
Go to Newsletter
The Sanitization Revolution: A Global Powerhouse Whitepaper
The Sanitization Revolution: A Global Powerhouse Whitepaper
Sanitization is a key factor in rural and urban India. The lack of adequate sanitization is a very pressing challenge in India. The sanitization related diseases take a heavy toll of lives especially children’s lives and are a drain on productivity and incomes. When India becomes more populous, its growth presents major challenges in providing environmental services like water, solid waste management, sanitation, & drainage. Nevertheless, promising projects are underway in both rural and urban settings to tackle the health problems. The purpose of this whitepaper is to give an overall scenario of the global...
Go to Newsletter
Herpes Zoster Oticus Newsletter
Herpes Zoster Oticus
Herpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A result of reactivation of varicella-zoster virus infection, it manifests as severe otalgia and associated cutaneous vesicular eruption. Also called Ramsay Hunt Syndrome or Ramsay Hunt Syndrome type II, it is a common complication of shingles. DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers. The newsletter is a brief introduction of the indication – Herpes zoster oticus, with its epidemiological analysis, treatment approaches, unmet needs in the market, and upcoming therapies in the pipeline. Also called Ramsay Hunt Syndrome or Ramsay Hunt...
Go to Newsletter
Digital Therapeutics in Mental Health Whitepaper
Digital Therapeutics in Mental Health Whitepaper
Digital therapies are evidence-based clinical approaches powered by software applications designed to prevent, control or treat a particular disease or condition. While advances in technology-assisted therapies evolve, digital therapy is evolving as a tool for treating mental well-being and addiction. Digital therapies have the ability to close patient care gaps, minimize time demands for providers and increase the effectiveness of pharmaceuticals, offering stakeholders hope across the healthcare delivery spectrum. The purpose of this whitepaper is to show the current trend, advances, and developments in the world of mental health inflicted through the usage of digital therapeutics.
Go to Newsletter
Warm Autoimmune Hemolytic Anemia Newsletter
Warm Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia (AIHA) is a rare acquired autoimmune disease. It is caused by the dysfunction in the immune system in which the immune system attacks its red blood cells considering them foreign substances. If the hemolysis takes place at 37 °C, it is referred to as Warm autoimmune hemolytic anemia. WAIHA accounts for 60-70% of the total AIHA cases. DelveInsight's brings another addition to its Newsletter Series, focusing on rare, life-threatening disease of the blood. The newsletter provides a brief introduction of the indication - Warm autoimmune hemolytic anemia, its epidemiological analysis, prevalence, marketed therapies, unmet needs, and pipeline therapies in the market.
Go to Newsletter
Exocrine Pancreatic Insufficiency Newsletter
Exocrine Pancreatic Insufficiency
A degenerative disease, Exocrine Pancreatic Insufficiency (EPI), is a consequence of insufficient production and secretion of pancreatic digestive enzymes, which leads to maldigestion in the duodenum. Know more about the Exocrine Pancreatic Insufficiency, its pathophysiology, manifestations, epidemiological scenario, and available treatment modalities by filling up the form towards the right. Get insights into the Exocrine Pancreatic Insufficiency market landscape, upcoming therapies, and key pharma companies transforming EPI market outlook through our newsletter.Through its newsletter, DelveInsight aims to provide rich insights into several diseases for a better understanding of the disease,
Go to Newsletter
Digital Health Transformation: 2020 Roadmap for Innovation Whitepaper
Digital Health Transformation: 2020 Roadmap for Innovation Whitepaper
The Digital Era has officially hit Prime Time. Currently, the potentiality to digitally transform a patient's healthcare service experience is becoming a significant competitive parameter for organizations, hospitals, and the whole healthcare system within. The impact of the digitalization of health services is expected to be progressively profound in the future. The purpose of the whitepaper is to generate awareness regarding the innovations related to healthcare services.
Go to Newsletter
Von Hippel-Lindau (VHL) syndrome Newsletter
Von Hippel-Lindau (VHL) syndrome
An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors and fluid-filled sacs (cysts) in up to ten different parts of the body including the brain, spine, eyes, kidneys, pancreas, adrenal glands, inner ears, reproductive tract, liver, and lungs. The disease has no cure; however, timely diagnosis can significantly improve the course of the disease. If left undetected or untreated, it can result in permanent brain damage and even death. However, a lot of research is ongoing, and several pharma players are working to find a standard treatment for VHL syndrome. Know about the ongoing R&D,
Go to Newsletter
The Ophthalmic drug delivery therapeutics for retinal disorders Whitepaper
The Ophthalmic drug delivery therapeutics for retinal disorders Whitepaper
Delivery of therapeutics to the human eye is among the most interesting endeavours a formulator can take on, but also one of the most challenging. The anatomy and chemical make-up of the eye make it highly resistant to therapeutic penetration. Successfully circumventing these protective barriers requires intimate knowledge of the constraints of ophthalmic delivery as well as specialized formulation and development expertise. According to WHO, Drug delivery to the eye in particular is expected to experience the largest growth in the next five years and 55% of debilitating ocular..
Go to Newsletter
Adult Onset Still's disease Newsletter
Adult Onset Still's disease
Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthritis that affects most people before the age of 45. The symptoms of the disease usually begin with a high fever that spikes once or twice a day, along with the development of a salmon-pink rash on the trunk, arms, or legs. Recently, the AOSD market welcomed it is the first ever the USFDA approved therapy. Know more about the AOSD market, treatment guidelines, and recent approvals through our newsletter.
Go to Newsletter
Prader-Willi syndrome Newsletter
Prader-Willi syndrome
A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning of genes in a particular region of chromosome 15. Genetic testing confirms the definitive diagnosis of the condition. The hallmark of PWS is a constant sense of hunger and obesity, and it affects approximately 1 out of every 15,000 births and has standard treatment. The newsletter by DelveInsight offers a brief overview of the indication, its subtypes, and its symptoms. It focuses on the epidemiological trends segmented into geographies in the 7MM, ethnicity, gender, total, and diagnosed cases.
Go to Newsletter
Hospital-acquired bacterial pneumonia/ Ventilator-associated bacterial pneumonia Newsletter
Hospital-acquired bacterial pneumonia/ Ventilator-associated bacterial pneumonia
Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infections (HAIs) and hospital-acquired infections. It is often seen in patients admitted to ICU wards. About 1 in 10 people admitted to hospitals contract HAIs. The infection causes a financial burden on patients and is a significant cause of morbidity and mortality. DelveInsight, through its newsletter series, brings to light an overview of the infection, underlying causes, etiology, and symptoms.
Go to Newsletter
Familial chylomicronemia syndrome Newsletter
Familial chylomicronemia syndrome
A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 million people that prevents the body from breaking down fats. The rarity of the disorder makes it challenging to manage, diagnose, and understand the disease clinically. The Familial chylomicronemia syndrome market lacks any approved therapy, and at present, the dietary restriction is the mainstay of the treatment. Gain more insights into the disease, its causes, symptoms, epidemiological insights, and available therapeutic options through DelveInsight's newsletter.
Go to Newsletter
Hereditary ATTR (hATTR) Amyloidosis Newsletter
Hereditary ATTR (hATTR) Amyloidosis
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein in the body's organs and tissues. Hereditary ATTR (hATTR) amyloidosis is the most common form of ATTR; nevertheless, it is a very rare disease. As per DelveInsight, Hereditary ATTR Amyloidosis diagnosed prevalence was recorded to be the highest in the United States, with a 10.2% growth rate. Pharma companies like Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, and many others are accelerating the Hereditary transthyretin amyloidosis market forward.
Go to Newsletter
Neuroendocrine tumors Newsletter
Neuroendocrine tumors
Neuroendocrine tumors (NET) are a rare kind neoplasm that arises from cells of the endocrine (hormonal) and nervous systems. These tumors commonly occur in the intestine, where they are often called carcinoid tumors; however, they can also be found in the pancreas, lungs, and the rest of the body. In the year 2017, the total number of the prevalent cases of Neuroendocrine tumors in the 7 MM was estimated to be 454,000 cases.The newsletter by DelveInsight offers a brief overview of the indication, its subtypes, and symptoms. It also brings into focus the epidemiological trends segmented into geographies in the 7MM, ethnicity, gender, total, and diagnosed cases.
Go to Newsletter
Retinitis pigmentosa Newsletter
Retinitis pigmentosa
Retinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye is inflicted upon the light-sensitive tissue – the retina, which is the leading cause of blindness. The disease affects 1 in 3,000 to 1 in 4,000 people in the world, which sums its total prevalence to be approximately 1.77 to 2.35 million people globally. However, still, there is no standard or approved therapy to cure the disease. DelveInsight is adding another Newsletter to its series that focuses on the sight-threatening disease. The newsletter provides a brief introduction of the indication - Retinitis pigmentosa, its epidemiological analysis.
Go to Newsletter
Ataxia Telangiectasia Newsletter
Ataxia Telangiectasia
An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune system, along with the other body parts. The disease causes difficulties in coordinating movements beginning in early childhood, usually before the age of 5.A result of a mutation in the ATM gene, Ataxia Telangiectasia, approximately affects one in 40,000 – 100,000 live births in the US. Know more about the Ataxia Telangiectasia, its pathophysiology, manifestations, epidemiological scenario, and available treatment modalities by filling up the form towards the right.
Go to Newsletter
Chronic inflammatory demyelinating polyneuropathy market Newsletter
Chronic inflammatory demyelinating polyneuropathy market
A rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms, Chronic inflammatory demyelinating polyneuropathy (CIDP) is a result of the damaged myelin sheath of the peripheral nerves. CIDP is a treatable disorder. However, despite the availability of disease-modifying treatment options, CIDP patients continue to struggle. At present, several pharma companies are investing in continued research to discover novel targets to provide better treatment options to patients.
Go to Newsletter
Focal Segmental Glomerulosclerosis Newsletter
Focal Segmental Glomerulosclerosis
A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease with prevalent cases of 196,333 in the 7MM as estimated by DelveInsight in 2017. However, poor knowledge of the disease remains a major concern. At present, there is a dire need for heightened R&D in the field for a better understanding of the physio-pathology of FSGS for better diagnostic tests and treatments. Know more about the condition, its causes, symptoms, epidemiological insights and available therapeutic options through DelveInsight’s newsletter. The newsletter covers the recent happenings in Focal Segmental Glomerulosclerosis Market
Go to Newsletter
Healthcare Performance Whitepaper
Healthcare Performance Whitepaper
Healthcare Performance Improvement provides proven methods for sustaining and building a culture of safety. In order to build a new, patient-centric continuum of care, a fundamental restructuring of the healthcare system is the most important step. Healthcare systems have several performance improvement strategies that often are not in synchronization with the emerging marketplace requirements. The traditional approaches to performance improvement cannot alone offset various kinds of declines for most organizations.
Go to Newsletter
Raynauds phenomenon Newsletter
Raynaud's phenomenon
Raynaud’s phenomenon (RP) is a condition that results in discoloration of fingers or toes caused by episodic vasospasm and ischemia of the extremities in response to cold or emotional stimuli. Usually, the condition is visible in distal digits; however, the discoloration can also be seen in the nose, ears and tongue. With no cure at hand, Raynaud’s phenomenon has symptomatic treatment options available in the market. Gain more insights into the Raynaud’s phenomenon, its causes, symptoms, epidemiological insights and available therapeutic options through DelveInsight’s newsletter.
Go to Newsletter
Paroxysmal Nocturnal Hemoglobinuria Whitepaper
Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction of red blood cells, blood clots, and an impaired bone marrow caused due to the mutation in the PIGA (Phosphatidylinositol glycan class A) gene. DelveInsight's brings another addition to its Newsletter Series focusing on a life-threatening disease of the blood. The newsletter provides a brief introduction of the indication - Paroxysmal Nocturnal Hemoglobinuria, its epidemiological analysis, preponderance in different populations, treatment approaches, unmet needs in the market, and upcoming therapies in the future.
Go to Newsletter
Fibrodysplasia Ossificans Progressiva Whitepaper
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification of the connective tissues and muscle tissues, such as ligaments and tendons. They are replaced by bone (ossified), forming extra-skeletal or heterotopic bone that constrains movement. Being a rare disorder, and no diagnostics indicator and overall lack of understanding delays the treatment of the disease.However, through its newsletter series, DelveInsight, aims to increase awareness about the indication, its underlying causes, etiology, signs and symptoms.
Go to Newsletter
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies Whitepaper
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies
Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from cancer help to achieve complete remission that many other times, traditional chemotherapies fail to deliver. Thus, cellular immunotherapies for refractory/relapsed Haematological Malignancies patients are a novel treatment approach that helps to eliminate the chances of remission in malignancy patients. Through the whitepaper, DelveInsight brings to its clients and readers the gradual shift in the way the cures and treatment regimens for cancer are being preferred.
Go to Newsletter
Evolution of Precision Medicine in Oncology Whitepaper
Evolution of Precision Medicine in Oncology
Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailoring the treatment approach and regiment cancer patients are administered. Unlike traditional chemotherapies, Precision Medicine is targeted therapies that target the genetic mutations and locations of cancer. Through the whitepaper, DelveInsight brings to its clients and readers the journey of one of the most looked upon and emerging therapies in the oncology that is curated precisely to offer best-class treatment - Precision Medicine.
Go to Newsletter
COVID-19 Whitepaper
COVID-19
Over the last months, the world has faced one of the most unexpected challenges in the form of a novel coronavirus, SARS-CoV-2, infection. Through the whitepaper, DelveInsight aims to make its clients and users aware of the exact scenario of the novel coronavirus SARS-CoV-2 and the disease COVID-19. The whitepaper is a detailed description of SARS-CoV-2 virus, its morphology and pathophysiology, and the trends of the patients affected, most prevalent symptoms, as well as understand the asymptomatic traits.
Go to Newsletter
Generalized Myasthenia Gravis Newsletter
Generalized Myasthenia Gravis
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skeletal muscles, including the muscles of arms and legs, leading to breathing difficulty and mobility issues. When the muscles affected are from multiple muscle groups throughout the body, it is called generalized myasthenia gravis (gMG).With a higher diagnosed prevalence of generalized Myasthenia Gravis in the United States of approximately 32,188 cases, gMG has an equal prevalent ratio in males and females.
Go to Newsletter
Gaucher Disease Newsletter
Gaucher Disease
The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosidase (GCase), an enzyme required for the break-down of glucocerebroside thus causing a build-up in areas like the spleen, liver, and bone marrow. With an equal prevalence in males and females, the overall frequency of Gaucher Disease is approximately 1 in 50,000 to 1 in 100,000 live births. The newsletter by DelveInsight offers a crisp overview of the indication, its subtypes and symptoms.
Go to Newsletter
Duchenne Muscular Dystrophy Newsletter
Duchenne Muscular Dystrophy
A genetic disorder, Duchenne Muscular Dystrophy (DMD), is a progressive form of muscular dystrophy with a higher preponderance in males; however, in some rare cases, it can occur in females too. As per DelveInsight, the total prevalent population of Duchenne Muscular Dystrophy in the 7MM was found to be 31,386, whereas, total diagnosed prevalent population was found to be 26,678 in 2017. The newsletter will help the readers and clients to gain a perspective on the latest trends in the Duchenne Muscular Dystrophy Market, its epidemiology and the role of mutations that form the underlying cause of the disease.
Go to Newsletter
Cutaneous Lupus Erythematosus Newsletter
Cutaneous Lupus Erythematosus
An autoimmune disease in which the immune system attacks its healthy skin, Cutaneous Lupus Erythematosus, belongs to the family of Lupus Erythematosus (LE). Through the newsletter, DelveInsight brings to light about a condition that had a prevalence of 327,569 in the US alone in 2017. The newsletter provides an overview of the indication, symptoms, causes, and etiology. It also put forward the historical epidemiological trends listing its prevalence and incidence, with the 11-year forecast.
Go to Newsletter
Complex Regional Pain Syndrome Newsletter
Complex Regional Pain Syndrome
A chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believed to be caused by injury, or malfunction of, the peripheral and central nervous systems. DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers. The newsletter is a brief introduction of the indication - Complex Regional Pain Syndrome, with its epidemiological analysis, preponderance, treatment approaches, unmet needs in the market, and upcoming therapies in the horizon.
Go to Newsletter
Fragile X Syndrome Newsletter
Fragile X Syndrome
Fragile X Syndrome is a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people, and is a result of mutation associated with the gene FMR1. DelveInsight's newsletter series brings to light an overview of Fragile X syndrome, underlying causes, risk factors, etiology, and symptoms. The newsletter provides a brief scenario of the prevalence and incidence of the disease, present treatment approaches and the therapies and drugs in the pipeline for the disease.
Go to Newsletter
Pompe disease Newsletter
Pompe disease
An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females.
Go to Newsletter
Impact of BREXIT on Pharma Space Newsletter
Impact of BREXIT on Pharma Space
BREXIT, the 'EXIT' of 'BRITAIN' from 'EUROPEAN UNION', shook the whole world when the United Kingdom voted in the favor of leaving the EU. This was mainly done to access greater control of the country's borders as well as economy, which also led to major impact on various countries that have conducted business and trade within the UK borders. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenario.
Go to Newsletter
An Abundance Of Rare Newsletter
An Abundance Of Rare
Though appear rare, rare diseases are far from being rare. With over 7,000 rare disease affecting millions worldwide, Rare disease pose a huge burden on the global healthcare system, affecting the quality of lives of patients. There is still a lack of understanding in the abundance of the rare diseases prevalent globally and treatment approaches that are being adapted. DelveInsight, with its new newsletter series, aims to put forward enriching content related to various rare diseases for a crystal-clear picture of the rare disease, their therapies, and market trends.
Go to Newsletter
Cancer Globally (Vol. 1, Issue 1) Newsletter
Cancer Globally (Vol. 1, Issue 1)
Cancer has gripped the human society in its clutches in such a way that there has been many advancements to treat the same, but with little success. The full extent of the disease can only be measured by the population that it has plagued, and how varied it has become over the course of years. Cancer by Numbers provide us with the degree of devastation it has incurred among various populations, and provides us with a better idea on the level of progress needed to eradicate this morbid indication. It also sheds light on the blockbuster drugs along with potential therapies for the cancer.
Go to Newsletter
Cancer in The United States(Vol 1, Issue 2) Newsletter
Cancer in The United States(Vol 1, Issue 2)
US Cancer Statistics show that more than half a million suffer from this disease, which is the second leading cause of death in the country. The newsletter Cancer in the US substantiates the increasing incidence and prevalence of major cancer sub-types in the American patient population, drawing conclusions related to the seriousness of the matter. This edition further points out to the top selling cancer drugs in the country and how new and innovative therapies are being researched to limit the devastating impact of this debilitating disease. Read on to know more
Go to Newsletter